US FDA declines to approve Summit Therapeutics' lung cancer drug
SMMT•The US FDA declined to approve Summit Therapeutics' lung cancer drug, a setback to efforts to bring a new treatment to patients whose cancer has progressed and who have limited options.
1. FDA decision
The US FDA declined to approve Summit Therapeutics' lung cancer drug on Sunday. The decision dealt a setback to efforts to bring a new treatment to patients whose cancer has progressed and who have limited options.
